Treatment and diagnosis of autoantibody-mediated eye diseases
AssigneeThe Board of Trustees of the University of Illinois
InventorSandeep Jain
Life of this patent
Estimating the term…
Abstract
The present disclosure provides an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount or deleterious actions of autoantibodies on the ocular surface, such as IgG; In particular, the present disclosure provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disease that can cause symptoms of ocular discomfort, keratitis, dry eye disease, symblepharon formation, fornix foreshortening, eyelid margin/conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.
Claims21
-84. (canceled)
An ophthalmic composition formulated for administering topically to an ocular surface, said ophthalmic composition comprising:
- (a) a pharmaceutically acceptable ophthalmic excipient;
- and
- (b) a therapeutically effective amount of a pharmaceutically active compound comprising a pooled human immunoglobulin G (IgG),
- wherein said pharmaceutically active compound is ocularly active and is capable of treating a clinical condition comprising (i) an inflammatory ocular surface or intraocular disease;
- or (ii) an immunological ocular surface or intraocular disease.
The ophthalmic composition according to claim 84, wherein said pooled human IgG comprises a pooled human IgG1, IgG2, IgG3, IgG4, or a combination thereof.
The ophthalmic composition according to claim 84 further comprising a growth factor.
The ophthalmic composition according to claim 84 further comprising an ocular surface regeneration promoting protein.
A method for treating an ocular disease or condition in a subject comprising administering to a subject in need of such a treatment a therapeutically effective amount of an ophthalmic composition of claim 84, wherein said ocular disease or condition comprises:
- (i) an inflammatory ocular surface disease or condition,
- (ii) an inflammatory intraocular disease or condition,
- (iii) an immunological ocular surface disease or condition,
- (iv) an immunological intraocular disease or condition, or
- (v) a combination thereof.
An ophthalmic composition formulated for a topical administration to an ocular surface, said ophthalmic composition comprising:
- (a) a pharmaceutically acceptable ophthalmic excipient;
- and
- (b) a pooled human plasma, serum, or blood comprising from about 0.01% w/v to about 10% w/v of immunoglobulin G (IgG).
An ophthalmic composition formulated for a topical administration to an ocular surface, said ophthalmic composition comprising:
- (a) a pharmaceutically acceptable ophthalmic excipient;
- and
- (b) about 5% w/v of pooled human immunoglobulin G (IgG).
Dependencies are inferred from the claim text.